TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
27 hedge funds and large institutions have $2.9M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 9 closing their positions.
16% less funds holding
Funds holding: 32 → 27 (-5)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
85% less capital invested
Capital invested by funds: $18.8M → $2.9M (-$15.9M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$139K |
| 2 |
HF
HRT Financial
New York
|
+$44.9K |
| 3 |
VF
Virtu Financial
New York
|
+$25.9K |
| 4 |
Millennium Management
New York
|
+$8.59K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.49K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$79.1K |
| 2 |
Bank of New York Mellon
New York
|
-$51.5K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$37.8K |
| 4 |
BlackRock
New York
|
-$34.8K |
| 5 |
XSC
X-Square Capital
Guaynabo,
Puerto Rico
|
-$34K |
TCON Hedge Fund Activity: Q2 2023 in Review
27 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q2 2023, worth a combined $2.9M — down 85% from $18.8M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of TCON and 4 opened new positions — a net loss of 5 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was Vanguard Group, adding an estimated $139K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $79.1K sold.
- 27 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q2 2023, down from 32 in Q1 2023.
- Funds reported $2.9M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q2 2023, down 85% quarter-over-quarter.
- 4 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q2 2023 and 9 closed out, a net change of -5 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q2 2023 was Vanguard Group, an estimated $139K added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q2 2023 was Susquehanna International Group, an estimated $79.1K sold.
Based on aggregated 13F filings for Q2 2023.